FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,346,000 | -55.5% | 2,050,000 | 0.0% | 0.48% | -43.6% |
| Q2 2023 | $9,758,000 | -16.5% | 2,050,000 | 0.0% | 0.85% | -11.4% |
| Q1 2023 | $11,685,000 | -43.5% | 2,050,000 | 0.0% | 0.96% | -39.9% |
| Q4 2022 | $20,684,500 | -55.0% | 2,050,000 | 0.0% | 1.60% | -46.9% |
| Q3 2022 | $45,941,000 | -11.7% | 2,050,000 | -2.4% | 3.02% | -31.4% |
| Q2 2022 | $52,038,000 | -60.5% | 2,100,000 | -38.2% | 4.40% | -25.6% |
| Q1 2022 | $131,818,000 | -33.7% | 3,400,000 | 0.0% | 5.91% | +5.4% |
| Q4 2021 | $198,934,000 | -1.3% | 3,400,000 | 0.0% | 5.61% | +11.8% |
| Q3 2021 | $201,518,000 | -31.7% | 3,400,000 | 0.0% | 5.02% | -33.0% |
| Q2 2021 | $295,086,000 | +5.3% | 3,400,000 | 0.0% | 7.49% | -10.3% |
| Q1 2021 | $280,330,000 | +1.1% | 3,400,000 | +11.5% | 8.35% | +1.6% |
| Q4 2020 | $277,337,000 | +127.5% | 3,050,000 | 0.0% | 8.22% | +50.5% |
| Q3 2020 | $121,909,000 | +16.5% | 3,050,000 | 0.0% | 5.46% | -11.9% |
| Q2 2020 | $104,646,000 | +84.8% | 3,050,000 | +19.6% | 6.19% | +3.0% |
| Q1 2020 | $56,636,000 | +13.5% | 2,550,000 | 0.0% | 6.01% | +31.0% |
| Q4 2019 | $49,904,000 | -99.9% | 2,550,000 | 0.0% | 4.59% | +12.0% |
| Q3 2019 | $39,601,500,000 | -23.5% | 2,550,000 | 0.0% | 4.10% | -15.4% |
| Q2 2019 | $51,765,000,000 | +115436.6% | 2,550,000 | 0.0% | 4.84% | -1.5% |
| Q1 2019 | $44,804,000 | +36.9% | 2,550,000 | 0.0% | 4.92% | -12.1% |
| Q4 2018 | $32,717,000 | -21.2% | 2,550,000 | 0.0% | 5.60% | +10.9% |
| Q3 2018 | $41,540,000 | +40.9% | 2,550,000 | -1.9% | 5.05% | +22.5% |
| Q2 2018 | $29,484,000 | +16.2% | 2,600,000 | 0.0% | 4.12% | -7.6% |
| Q1 2018 | $25,376,000 | +59.7% | 2,600,000 | 0.0% | 4.46% | +15.4% |
| Q4 2017 | $15,886,000 | +629.4% | 2,600,000 | +372.7% | 3.87% | +529.1% |
| Q3 2017 | $2,178,000 | +22.2% | 550,000 | 0.0% | 0.62% | -6.7% |
| Q2 2017 | $1,782,000 | – | 550,000 | – | 0.66% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |